Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective Giovany Orozco-LealEugenie Evelynne JohnsonStephen Rice Commentary 20 November 2023 Pages: 133 - 136
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum Daniel GladwellOriana CianiStephen Palmer Current Opinion 22 November 2023 Pages: 137 - 144
A Framework for the Fair Pricing of Medicines Mike Paulden Leading Article Open access 08 December 2023 Pages: 145 - 164
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments Alex J. TurnerCormac SammonJoshua Ray Practical Application Open access 27 October 2023 Pages: 165 - 176
Systematic Review of the Relative Social Value of Child and Adult Health Tessa PeasgoodMartin Howellthe Quality Of Life in Kids: Key evidence to strengthen decisions in Australia (QUOKKA), Tools for Outcomes Research to measure, value Child Health (TORCH) project teams Systematic Review Open access 09 November 2023 Pages: 177 - 198
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects Ramesh LamsalE. Ann YehWendy J. Ungar Systematic Review Open access 09 November 2023 Pages: 199 - 217
Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study Javier MarOliver IbarrondoMaĆra Aguiar Original Research Article Open access 01 November 2023 Pages: 219 - 229
Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States Christopher W. YeeMichael J. HarveyNoam Y. Kirson Original Research Article Open access 07 November 2023 Pages: 231 - 247